Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) entered definitive agreements for up to $10 million in cash financing, including $2.5 million of non-redeemable, non-convertible preferred stock and two secured promissory notes of $2.72 million and $5.0 million.
The notes accrue 8% and 5% annual interest, mature in 18 months, and interest will be partially offset by bank deposits. Net proceeds will support continued enrollment of the pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
Updated Phase 2 OVATION 2 data show median overall survival improving from 11.1 to 14.7 months, and a 24.2‑month median increase versus standard chemotherapy when IMNN-001 and PARP inhibitors are added.
IMUNON (NASDAQ: IMNN) reported first quarter 2026 net loss of $4.3 million, or $0.84 per share, with operating expenses of $4.3 million and cash and equivalents of $4.8 million.
Phase 2 OVATION 2 data for IMNN-001 showed median overall survival gains up to 24.2 months and a favorable safety profile, supporting the ongoing Phase 3 OVATION 3 trial, which has FDA-aligned protocol and a defined path to BLA filing.
IMUNON (NASDAQ: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to report first quarter results for the period ended March 31, 2026 and provide an update on Phase 3 clinical development of lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.
Live dial-in and webcast access will be provided; an audio replay will be available for 90 days.
IMUNON (Nasdaq: IMNN) reported 2025 results and clinical progress on IMNN-001 for newly diagnosed advanced ovarian cancer. Final Phase 2 OVATION 2 data show continued median overall survival improvement: 14.7 months benefit (45.1 vs. 30.4 months) versus standard of care, and 24.2 months with PARP inhibitor maintenance (65.6 vs. 41.4 months).
Corporate actions include a December 2025 at-the-market registered direct offering (~$7.0M) and a strategic reorganization; 2025 net loss was $14.5M and year-end cash was $8.8M.
IMUNON (Nasdaq: IMNN) reported final Phase 2 OVATION 2 results showing an improved median overall survival (OS) benefit for IMNN-001 plus standard chemotherapy: a 14.7-month OS increase (45.1 vs. 30.4 months) versus SoC alone. Women receiving IMNN-001 plus PARP inhibitor maintenance showed a 24.2-month OS increase (65.6 vs. 41.4 months).
OVATION 2 randomized 112 patients. IMUNON says Phase 3 OVATION 3 enrollment is ahead of plan, currently open at seven sites with up to 43 sites considered and ~80 patients (~20% of 500 target) expected within a year; two interim OS analyses are planned.
IMUNON (Nasdaq: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its Phase 3 clinical program for IMNN-001.
To join, dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and reference Conference ID 4157104; a live webcast and a 90-day audio replay will be available. According to the company, the call will review 2025 results and clinical progress for IMNN-001.
IMUNON (Nasdaq: IMNN) announced a strategic reorganization to reduce nonessential headcount and redefine roles to lower operating expenses and prioritize its pivotal OVATION 3 Phase 3 ovarian cancer trial.
The company said Phase 3 enrollment remains ahead of schedule, and EVP/CSO Khursheed Anwer will retire effective February 20, 2026.
IMUNON (Nasdaq: IMNN) announced a registered direct offering to a single healthcare institutional investor for 1,939,114 shares of common stock (or pre-funded warrants) plus warrants to purchase up to 1,939,114 shares, at a combined purchase price of $3.61 per share and warrant (pre-funded warrant alternative at $3.6099).
The offering is expected to yield approximately $7.0 million gross, with warrants exercisable immediately at $3.482 and expiring five years from issuance; pre-funded warrants have a $0.0001 exercise price and do not expire. The offering will be made under the company’s Form S-3 shelf declared effective May 22, 2024, and is expected to close on or about December 31, 2025.
IMUNON (Nasdaq: IMNN) reported 2025 clinical and operational progress as it advances the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer and prepares toward a potential BLA filing. Key Phase 2 results cited include a 13-month median overall survival (OS) extension (HR 0.70) and an HR of 0.42 in a PARP inhibitor maintenance subgroup. Ongoing MRD translational data show IL-12 induction in macrophages, tumor microenvironment inflammation, lower MRD positivity and improved CRS/PFS signals. Company cites cost reductions in cGMP manufacturing and estimates $30 million to fund OVATION 3 HRD+ subgroup activities. Fast Track and Orphan Drug designations remain in place.
IMUNON (NASDAQ: IMNN) reported third quarter 2025 results and clinical progress on November 13, 2025. The company highlighted a median 13-month overall survival (OS) benefit observed with IMNN-001 in OVATION 2 and translational data showing tumor microenvironment shifts (CD8+ increases, reduced IDO/PD-L1/Treg) in 50-80% and 65-80% of paired samples. IMUNON described expanded Phase 3 OVATION 3 enrollment and an adaptive, event-driven trial design aligned with FDA precedents.
Financially, Q3 net loss was $3.4M (vs $4.8M prior year), operating expenses fell ~30%, and cash was $5.3M, which the company says funds operations into Q1 2026 while it pursues selective financing.